outside normal laboratory values). Fe-male subjects were postmenopausal orsurgically sterile or using contraceptivesfor at least 3 months before screening andcontinuing throughout the study. Sub-jects were excluded if they had used met-formin, thiazolidinediones, meglitinides,/H9251-glucosidase inhibitors, exogenous in- sulin therapy, or weight-loss drugs withinthe prior 3 months. Further exclusion cri-teria included therapy with corticoste-●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● From the1Diabetes Care Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina; the2Veterans Administration Medical Center, University of California, San Diego, California; and 3Amylin Pharmaceuticals, San Diego, California. Address correspondence and reprint requests to Alain D. Baron, MD, Senior Vice-President, Clinical Research, Amylin Pharmaceuticals, 9360 Towne Centre Dr., Suite 110, San Diego, CA 92121. E-mail:abaron@amylin.com.